SLC2A1 and depressive disorder: Based on the positive relationship between depression and glucose metabolism, DEXA administration was found to induce MDD-like pathology through high glucose metabolism associated with increased expression of GLUT1 and GLUT3, along with increased levels of hexokinase and pyruvate kinase in the brain.